For heart failure patients, accurate and non-invasive monitoring of lung fluid is a critical need. Sensible Medical Innovations Ltd., the company behind the ReDS system designed to address this challenge, has now secured $20.0M in new funding.
The capital will support the continued development and deployment of its core technology: a non-invasive fluid status monitor. This ReDS system provides accurate measurement and monitoring of lung fluid, offering a vital tool for clinicians managing heart failure patients and aiming to improve patient outcomes.
.png&w=3840&q=75)
.png&w=3840&q=75)
